Home › Compare › SWDHF vs ABBV
SWDHF yields 1.18% · ABBV yields 3.06%● Live data
📍 SWDHF pulled ahead of the other in Year 5
Combined, SWDHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SWDHF + ABBV for your $10,000?
Skyworth Group Limited, an investment holding company, researches and develops, manufactures, sells, and exports consumer electronic products. It operates through Multimedia Business, Smart Systems Technology Business, Smart Appliances Business, and New Energy Business segments. The company offers smart TV systems; home access systems, such as digital set-top boxes; smart white appliances, including air conditioners, refrigerators, washing machines, kitchen appliances, other products; LCD modules; automotive electronic systems; lighting products; security systems; and other electronic products, as well as internet value-added services. It is also involved in the property development and holding; trading of consumer electronic products; and sale and installation of photovoltaic power station for residential use, as well as financing and treasury management activities. In addition, the company engages in the maintenance and repair of home appliances; construction development business; finance leasing; and logistics services, as well as operates industrial parks. It has operations in the People's Republic of China, rest of Asia, Europe, the Middle East, the United States, Oceania, and Africa. The company was formerly known as Skyworth Digital Holdings Limited and changed its name to Skyworth Group Limited in June 2019. Skyworth Group Limited was founded in 1988 and is headquartered in Quarry Bay, Hong Kong.
Full SWDHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.